296
edits
Changes
NGS
,→Challenges
==Challenges==
* Bad coverage of pharmacogenes. This most seriously affects WES.
* CNV and other haplotype calling is challenging due to short read. NGS requires ''in silico'' CNV and haplotype estimation. Haplotype calling can e.g. be performed by [http://faculty.washington.edu/browning/beagle/beagle.html Beagle] or [http://dx.doi.org/10.1038/ng.3679 Eagle2].
* Variants in homologous regions are hard to capture. Notably, the genes CYP2D6 and CYP2A6 are challenging. The CYP2D6 genotyping tool used by PharmCAT is [https://www.nature.com/articles/npjgenmed201639 Astrolabe].
